Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01253967
Other study ID # 110436
Secondary ID
Status Completed
Phase N/A
First received November 30, 2010
Last updated April 9, 2015
Start date February 2008
Est. completion date January 2010

Study information

Verified date April 2015
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority Romania: Minister of Health
Study type Observational

Clinical Trial Summary

The purpose of this hospital based study is to estimate the proportion of rotavirus gastroenteritis in children < 5 years of age in Romania.


Description:

The study consist of a main study and a health economics study

Main study: The study will focus on three different groups of patients:

- Subjects who are hospitalised for acute gastroenteritis.

- Subjects who visit an emergency room for acute gastroenteritis.

- Subjects who have rotavirus positive laboratory results and developed acute gastroenteritis at least 48 hours after hospitalisation.

Health economics study: for a subset of subjects, additional economic data will be gathered by completing a questionnaire


Recruitment information / eligibility

Status Completed
Enrollment 1234
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Both
Age group N/A to 5 Years
Eligibility Inclusion Criteria:

- A male or female child aged < 5 years at the time of admission. A child becomes ineligible on the day of her/his fifth birthday.

- A subject, who during the study period:

- Is hospitalised for acute gastroenteritis Or

- Visits an emergency room for acute gastroenteritis Or

- Has rotavirus positive laboratory results and develops acute gastroenteritis at least 48 hours after hospitalisation

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Procedure:
Collection of stool samples
Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
Other:
Health economics questionnaire
For a subset of subjects, additional economic data will be gathered by completing a questionnaire

Locations

Country Name City State
Romania GSK Investigational Site Bucharest
Romania GSK Investigational Site Bucharest
Romania GSK Investigational Site Cluj
Romania GSK Investigational Site Cluj Napoca
Romania GSK Investigational Site Constanta
Romania GSK Investigational Site Craiova
Romania GSK Investigational Site Sibiu
Romania GSK Investigational Site Timisoara

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Romania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of rotavirus gastroenteritis among all acute gastroenteritis hospitalisations of children < 5 years of age At least 12 months from study start No
Primary Proportion of rotavirus gastroenteritis among all acute gastroenteritis emergency room visits for children < 5 years of age At least 12 months from study start No
Primary Incidence of medical care associated rotavirus gastroenteritis among all hospitalised children < 5 years of age At least 12 months from study start No
Secondary Age distribution of children with rotavirus gastroenteritis At least 12 months from study start No
Secondary Percentage of rotavirus genotypes amongst all isolated strains in children < 5 years of age At least 12 months from study start No
Secondary Potential risk factors for rotavirus gastroenteritis At least 12 months from study start No
Secondary Rotavirus gastroenteritis associated costs At least 12 months from study start No
Secondary Proportion of acute gastroenteritis among all hospitalisations of children < 5 years of age At least 12 months from study start No
Secondary Proportion of community acquired acute gastroenteritis among all emergency room visits for children < 5 years of age At least 12 months from study start No
Secondary Seasonal distribution (if appropriate) of rotavirus among all children < 5 years of age At least 12 months from study start No
Secondary Severity of rotavirus among all children < 5 years of age At least 12 months from study No
Secondary Proportion of rotavirus gastroenteritis among all hospitalisations of children < 5 years of age At least 12 months from study start No
Secondary Proportion of community acquired rotavirus gastroenteritis among all emergency room visits for children < 5 years of age At least 12 months from study start No
See also
  Status Clinical Trial Phase
Completed NCT01435967 - Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™ N/A
Completed NCT00370318 - Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines Phase 3
Completed NCT00345956 - To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) Phase 3
Completed NCT00140686 - To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines Phase 3
Completed NCT00383903 - Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa Phase 2
Completed NCT00750893 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
Completed NCT00533507 - Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age Phase 3
Completed NCT00363545 - To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) Phase 3
Completed NCT02914184 - Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks Phase 3
Completed NCT00489567 - Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden N/A
Completed NCT01733862 - Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
Completed NCT00779779 - Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
Completed NCT00382772 - A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine). Phase 3
Completed NCT00729001 - Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants. Phase 2
Completed NCT00353366 - To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
Completed NCT01198769 - Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth. Phase 4
Completed NCT00385320 - Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months Phase 2
Completed NCT00432380 - A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants. Phase 2
Completed NCT01563159 - Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011 N/A
Completed NCT01339221 - Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium N/A